Design, construction, and in vitro analyses of multivalent antibodies

Area of Science:

• Immunology
• Biotechnology
• Cancer Therapeutics

Background:

• Antibodies (Abs) efficacy can be enhanced through dimerization or multimerization, which promotes target clustering and modulates cellular signaling.
• Mimicking these cross-linked structures is a strategy to improve therapeutic antibody potency.

Purpose of the Study:

• To design and generate novel multivalent antibodies with tandem Fab repeats to enhance therapeutic efficacy.
• To create and characterize various multivalent antibody formats, including tetravalent IgG1, tetravalent F(ab')2, and linear Fab multimers.

Main Methods:

• Antibody engineering to create tandem Fab repeats.
• Generation of multivalent antibody formats (tetravalent IgG1, tetravalent F(ab')2, linear Fab multimers).
• Testing the efficacy of multimerized antibodies against cell surface receptors HER2, death receptor 5, and CD20.

Main Results:

• Successfully generated multivalent antibodies with tandem Fab repeats.
• Demonstrated that multimerized antibodies targeting HER2, death receptor 5, and CD20 are more efficacious than parent monoclonal antibodies (mAbs).
• Observed enhanced triggering of antitumor cellular responses by the engineered multivalent antibodies.

Conclusions:

• Multivalent antibodies engineered with tandem Fab repeats can effectively mimic cross-linked antibodies, leading to improved therapeutic potency.
• These novel antibody formats show promise as both research reagents and potential novel therapeutics for cancer treatment.